Scholarlink

<p>This study investigates the development of a targeted drug delivery system utilizing zeolitic imidazolate framework-8 (ZIF-8)-based nanocarriers functionalized with Epithelial Cell Adhesion Molecule (EpCAM) aptamers to enhance the therapeutic efficacy of Doxorubicin (DOX) against EpCAM-positive cancer cells. The inherent properties of ZIF-8, including its high surface area, structural stability, and pH-responsive degradation, make it an ideal vehicle for controlled drug release. The encapsulation of Doxorubicin within ZIF-8 nanocarriers, combined with surface modification using aptamers, is designed to direct DOX delivery specifically to tumor cells, thereby reducing off-target cytotoxicity. Our findings demonstrate that EpCAM-targeted, PEGylated ZIF-8 nanocarriers significantly improve the therapeutic efficacy of DOX while minimizing toxicity in non-cancerous cells. Furthermore, in vivo studies confirmed superior tumor suppression accompanied by reduced systemic toxicity. This research underscores the potential of EpCAM-modified ZIF-8 nanocarriers as a highly promising and innovative strategy for targeted cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

EpCAM-targeted ZIF-8 nanocarriers for enhanced doxorubicin delivery in cancer therapy: a promising approach for tumor-specific drug release

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月24日

查看全文
  • Mojtaba Tarin,
  • Yazdan Hasani-Nourian,
  • Hosein Khoshsafar,
  • Hasan Bagheri

摘要

This study investigates the development of a targeted drug delivery system utilizing zeolitic imidazolate framework-8 (ZIF-8)-based nanocarriers functionalized with Epithelial Cell Adhesion Molecule (EpCAM) aptamers to enhance the therapeutic efficacy of Doxorubicin (DOX) against EpCAM-positive cancer cells. The inherent properties of ZIF-8, including its high surface area, structural stability, and pH-responsive degradation, make it an ideal vehicle for controlled drug release. The encapsulation of Doxorubicin within ZIF-8 nanocarriers, combined with surface modification using aptamers, is designed to direct DOX delivery specifically to tumor cells, thereby reducing off-target cytotoxicity. Our findings demonstrate that EpCAM-targeted, PEGylated ZIF-8 nanocarriers significantly improve the therapeutic efficacy of DOX while minimizing toxicity in non-cancerous cells. Furthermore, in vivo studies confirmed superior tumor suppression accompanied by reduced systemic toxicity. This research underscores the potential of EpCAM-modified ZIF-8 nanocarriers as a highly promising and innovative strategy for targeted cancer therapy.